Stockholm, October 12, 2021 – IRRAS, a global medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that Aarhus University Hospital in Aarhus, Denmark, one of the world's leading medical institutions, has initiated commercial use of its IRRAflow system for a variety of neurocritical applications.
The ACTIVE (Use of Active Fluid Exchange to Treat Intraventricular Hemorrhage (IVH)) clinical study will document the hospital’s use of the IRRAflow system and will compare it to the use of traditional passive ventricular drainage in EVD patients. Dr. Anders Korshøj, Associate Professor of Neurosurgery from Aarhus University Hospital, will serve as the study’s Principal Investigator and will coordinate the study, with expected expansion to multiple sites across Denmark.
"We are excited to finally begin treating patients with the IRRAflow system after lengthy delays due to COVID-19,” said Dr. Anders Korshøj. “As we treat more patients, we look forward to presenting the data from the ACTIVE trial to show how the system's combination of automated irrigation and controlled drainage may reduce complications and improve long-term clinical outcomes.”
"Beginning commercial use of our IRRAflow system at Aarhus University signifies an important milestone for IRRAS," said Will Martin, President and Chief Executive Officer of IRRAS. "Our team has worked hard throughout the COVID-19 pandemic to train the Aarhus team, and we look forward to this hard work resulting in positive patient outcomes and compelling clinical data with the ACTIVE trial.”
Traditional treatment options for IVH patients generally utilize an external ventricular drainage (EVD) system, which is a passive approach that relies solely on gravity to facilitate drainage. An EVD is currently the most common treatment option for intracranial bleeding or elevated intracranial pressure (ICP), but the technology’s shortcomings are well documented in scientific literature. Complications such as catheter blockage, infections, and incomplete drainage occur regularly and negatively impact patient outcomes, lengthen required treatment time, and significantly increase the overall cost of care.
The Department of Neurosurgery at Aarhus University Hospital is one of the leading neurosurgical departments in Denmark. The department is responsible for general neurosurgery and highly specialized neurosurgical procedures in Central Denmark Region. Moreover, the department is responsible for diagnostics, treatment, and care of patients with certain neurosurgical conditions in the entire country.
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
About Aarhus University and Aarhus University Hospital
Aarhus University Hospital belongs to the elite of university hospitals. Aarhus University Hospital develops and provides highly specialized medical treatment, research, and education at an international level. Aarhus University Hospital serves the citizens from across the central Denmark region in need of highly specialized treatment. For the last 14 years, Aarhus University Hospital has been appointed Denmark’s best hospital, and it currently ranks #32 on the Newsweek ranking of the world’s best hospitals.
Aarhus University (AU) is a dynamic, modern and highly international university. Since its founding in 1928, it has grown to become a leading public university with international impact and reach across the entire research spectrum. Out of over 17,000 universities worldwide, AU ranks among the top 100 universities in the world in several research areas and is considered among the top 25 universities in the European Union. AU stands out in particular in terms of research quality and the quality of degree programs. Regarding internationalization, AU is ranked in the top as well as no. 45 on THE’s ranking “Most International Universities in the World”.
For more information, please contact:
President and CEO
Director, Investor Relations
+46 102 11 5172
The information was released for public disclosure, through the agency of the contact person above, on October 12, 2021 at 08:30 (CET).